- Home
- TARS vs PGNY Comparison
TARS vs PGNY Comparison
Compare TARS & PGNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TARS | PGNY |
|---|---|---|
| Founded | 2016 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.5B |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | TARS | PGNY |
|---|---|---|
| Price | $71.93 | $25.69 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $89.00 | $26.50 |
| AVG Volume (30 Days) | 668.4K | ★ 1.1M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.21 | 14.04 |
| EPS | N/A | ★ 0.63 |
| Revenue | $451,360,000.00 | ★ $1,288,661,000.00 |
| Revenue This Year | $56.43 | $8.87 |
| Revenue Next Year | $30.19 | $9.76 |
| P/E Ratio | ★ N/A | $40.40 |
| Revenue Growth | ★ 146.71 | 10.40 |
| 52 Week Low | $48.20 | $16.10 |
| 52 Week High | $85.25 | $33.07 |
Technical Indicators
Market Signals| Indicator | TARS | PGNY |
|---|---|---|
| Relative Strength Index (RSI) | 67.86 | 32.85 |
| Support Level | $60.95 | $24.52 |
| Resistance Level | $74.39 | $27.26 |
| Average True Range (ATR) | 3.06 | 1.08 |
| MACD | 0.54 | -0.25 |
| Stochastic Oscillator | 95.61 | 6.00 |
Price Performance
Historical ComparisonAbout TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
About PGNY Progyny Inc.
Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.